Abstract
Breast cancer bone metastases may block normal bone remodeling and promote bone degradation, during which several signaling pathways and small non-coding miRNAs might all play a role. miRNAs and target mRNAs that might be associated with breast cancer bone metastasis were analyzed and selected using bioinformatics analyses based on online data. The 3′ untranslated region of key factors associated with breast cancer metastasis were examined for candidate miRNA binding site using Targetscan. The predicted binding was validated. The specific effects of single miRNA and dynamic effects of the miRNA-mRNA axis on breast cancer cell metastasis were investigated. miR-556-5p was downregulated in breast cancer samples according to online datasets and experimental analyses. In breast cancer cells, miR-556-5p overexpression inhibited, whereas miR-556-5p inhibition promoted cancer cell invasion and migration. Among key factors associated with breast cancer bone metastasis, parathyroid hormone related protein (PTHrP) 3′UTR possessed miR-556-5p binding site. Through direct binding, miR-556-5p negatively regulated PTHrP expression. In breast cancer cell lines, miR-556-5p inhibition promoted, whereas PTHrP silencing suppressed cancer cell migration, invasion, and epithelial-mesenchymal transition; the effects of miR-556-5p inhibition were partially reversed by PTHrP silencing. In summary, miR-556-5p targets PTHrP to modulate the cell migration and invasion of breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Please contact the authors for data requests.
Abbreviations
- EMT:
-
Epithelial-mesenchymal transition
- IHC:
-
Immunohistochemistry
- OPG:
-
Osteoprotegerin
- PTH:
-
Parathormone
- PTHrP:
-
Parathyroid hormone related protein
- RIP:
-
RNA immunoprecipitation
- TNFα:
-
Tumor necrosis factors α
References
Blair HC, Athanasou NA (2004) Recent advances in osteoclast biology and pathological bone resorption. Histol Histopathol 19:189–199. https://doi.org/10.14670/HH-19.189
Boras-Granic K, Wysolmerski JJ (2012) PTHrP and breast cancer: more than hypercalcemia and bone metastases. Breast Cancer Res 14:307. https://doi.org/10.1186/bcr3129
Boyce BF, Xing L (2008) Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473:139–146. https://doi.org/10.1016/j.abb.2008.03.018
Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176. https://doi.org/10.1053/ctrv.2000.0210
Cummins JM et al (2006) The colorectal microRNAome. Proc Natl Acad Sci USA 103:3687–3692. https://doi.org/10.1073/pnas.0511155103
Demirkan B (2013) The roles of epithelial-to-mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET) in breast cancer bone metastasis: potential targets for prevention and treatment. J Clin Med 2:264–282. https://doi.org/10.3390/jcm2040264
Fang YX, Gao WQ (2014) Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene 33:135–147. https://doi.org/10.1038/onc.2013.54
Garcia-Closas M et al (2013) Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet 45:392–398. https://doi.org/10.1038/ng.2561
Goh JN et al (2016) microRNAs in breast cancer: regulatory roles governing the hallmarks of cancer. Biol Rev Camb Philos Soc 91:409–428. https://doi.org/10.1111/brv.12176
Guise TA, Yin JJ, Thomas RJ, Dallas M, Cui Y, Gillespie MT (2002) Parathyroid hormone-related protein (PTHrP)-(1–139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo. Bone 30:670–676
Hashimoto Y, Akiyama Y, Yuasa Y (2013) Multiple-to-multiple relationships between microRNAs and target genes in gastric cancer. PLoS ONE 8:62589
Hastings RH, Laux AM, Casillas A, Xu R, Lukas Z, Ernstrom K, Deftos LJ (2006) Sex-specific survival advantage with parathyroid hormone-related protein in non-small cell lung carcinoma patients. Clin Cancer Res 12:499–506. https://doi.org/10.1158/1078-0432.CCR-05-0930
Jafari SH et al (2018) Breast cancer diagnosis: Imaging techniques and biochemical markers. J Cell Physiol 233:5200–5213. https://doi.org/10.1002/jcp.26379
Kim T, Reitmair A (2013) Non-coding rnas: functional aspects and diagnostic utility in oncology. Int J Mol Sci 14:4934–4968. https://doi.org/10.3390/ijms14034934
Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL (2000) TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106:1481–1488. https://doi.org/10.1172/JCI11176
Landgraf P et al (2007) A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129:1401–1414. https://doi.org/10.1016/j.cell.2007.04.040
Li J et al (2011) PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. J Clin Invest 121:4655–4669
Liao J, McCauley LK (2006) Skeletal metastasis: Established and emerging roles of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev 25:559–571. https://doi.org/10.1007/s10555-006-9033-z
Lo PK, Wolfson B, Zhou X, Duru N, Gernapudi R, Zhou Q (2016) Noncoding RNAs in breast cancer Brief Funct. Genomics 15:200–221. https://doi.org/10.1093/bfgp/elv055
Ma L (2016) MicroRNA and metastasis. Adv Cancer Res 132:165–207. https://doi.org/10.1016/bs.acr.2016.07.004
Mandujano-Tinoco EA, Garcia-Venzor A, Melendez-Zajgla J, Maldonado V (2018) New emerging roles of microRNAs in breast cancer. Breast Cancer Res Treat 171:247–259. https://doi.org/10.1007/s10549-018-4850-7
Martin TJ (2002) Manipulating the environment of cancer cells in bone: a novel therapeutic approach. J Clin Invest 110:1399–1401. https://doi.org/10.1172/JCI17124
Michailidou K et al (2013) Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 45:353–361. https://doi.org/10.1038/ng.2563
Nishihara M, Ito M, Tomioka T, Ohtsuru A, Taguchi T, Kanematsu T (1999) Clinicopathological implications of parathyroid hormone-related protein in human colorectal tumours. J Pathol 187:217–222. https://doi.org/10.1002/(SICI)1096-9896(199901)187:2%3c217::AID-PATH210%3e3.0.CO;2-0
Roodman GD (1999) Cell biology of the osteoclast. Exp Hematol 27:1229–1241
Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655–1664. https://doi.org/10.1056/NEJMra030831
Shi F, Zhang L, Liu X, Wang Y (2021) Knock-down of microRNA miR-556–5p increases cisplatin-sensitivity in non-small cell lung cancer (NSCLC) via activating NLR family pyrin domain containing 3 (NLRP3)-mediated pyroptotic cell death. Bioengineered 12:6332–6342
Stark MS et al (2010) Characterization of the melanoma miRNAome by deep sequencing. PLoS ONE 5:e9685. https://doi.org/10.1371/journal.pone.0009685
Suva LJ et al (1987) A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 237:893–896
Taipaleenmaki H et al (2015) Targeting of Runx2 by miR-135 and miR-203 impairs progression of breast cancer and metastatic bone disease. Cancer Res 75:1433–1444. https://doi.org/10.1158/0008-5472.CAN-14-1026
Taipaleenmaki H, Farina NH, van Wijnen AJ, Stein JL, Hesse E, Stein GS, Lian JB (2016) Antagonizing miR-218–5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells. Oncotarget 7:79032–79046. https://doi.org/10.18632/oncotarget.12593
Vimalraj S, Miranda PJ, Ramyakrishna B, Selvamurugan N (2013) Regulation of breast cancer and bone metastasis by microRNAs. Dis Markers 35:369–387. https://doi.org/10.1155/2013/451248
Wang Y et al (2018) A novel functional polymorphism of GSTM3 reduces clear cell renal cell carcinoma risk through enhancing its expression by interfering miR-556 binding. J Cell Mol Med 22:3005–3015. https://doi.org/10.1111/jcmm.13528
Wang Y, Zhou BP (2011) Epithelial-mesenchymal transition in breast cancer progression and metastasis. Chin J Cancer 30:603–611. https://doi.org/10.5732/cjc.011.10226
Wysolmerski JJ (2012) Parathyroid hormone-related protein: an update. J Clin Endocrinol Metab 97:2947–2956. https://doi.org/10.1210/jc.2012-2142
Yang Y et al (2015) Exosomes: a promising factor involved in cancer hypoxic microenvironments 22:4189–4195 https://doi.org/10.2174/0929867322666150825163318
Yang Y et al (2019) Recent advance in polymer based microspheric systems for controlled protein and peptide delivery. Cur Med Chem 26:2285–2296. https://doi.org/10.2174/0929867326666190409130207
Yin JJ et al (1999) TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103:197–206. https://doi.org/10.1172/JCI3523
Zhao W, Cao L, Zeng S, Qin H, Men T (2015a) Upregulation of miR-556–5p promoted prostate cancer cell proliferation by suppressing PPP2R2A expression. Biomed Pharmacother 75:142–147. https://doi.org/10.1016/j.biopha.2015.07.015
Zhou Y, Liu X, Lan J, Wan Y, Zhu X (2020) Circular RNA circRPPH1 promotes triple-negative breast cancer progression via the miR-556–5p/YAP1 axis. Am J Transl Res 12:6220–6234
Acknowledgements
None.
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no potential conflict of interest.
Ethical approval
The authors state that they have followed the principles outlined in the Declaration of Helsinki for all human experimental investigations and obtained the approval of the Research Ethics Committee at The First Hospital of Changsha approval. Besides, for investigations involving human subjects, informed consent has been obtained from the participants involved.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Zhou, R., Luo, Z., Yin, G. et al. MiR-556-5p modulates migration, invasion, and epithelial-mesenchymal transition in breast cancer cells via targeting PTHrP. J Mol Histol 53, 297–308 (2022). https://doi.org/10.1007/s10735-021-10056-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10735-021-10056-4